With an increased need for operational efficiency, while also leveraging new technologies such as AI, the landscape of ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...

The long-held practice is effective in pinpointing the emergence of known and unknown risks to clinical development, study ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

Nevertheless, there is no question that the research credit provides significant tax savings and should be considered by ...

Florence has been issuing its State of Technology Enabled Clinical Trials Report for five years now, so there is contextual ...

As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, Cluepoints, ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

The conundrum of missing data vs. inter-rater variability.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, discusses the importance of communicating with patients in their native ...